Hypophospatasia Treatment Market

Hypophospatasia Treatment Market Snapshot (2023 to 2033)

The global hypophosphatasia treatment market is expected to be valued at USD 16.13 Million in 2023. With the increasing alcohol consumption among people, the overall demand for hypophosphatasia treatment is projected to grow at a CAGR of 5.0% between 2023 and 2033, totaling around USD 26.27 Million by 2033.

According to the analysis of Future Market Insights, the hypophosphatasia treatment market is expected to fuel over the analysis period, attributed to the factors such as the focus of pharmaceutical companies as well as research Institutes on studying and developing new methods for the treatment of hypophosphatasia. For instance, Asfotase alpha is being studied by Alexion Pharmaceuticals and is in phase 2 of clinical trials for the study to evaluate its pharmacokinetic and pharmacodynamics in adult participants with pediatric-onset hypophosphatasia.

Additionally, the current treatment of hypophosphatasia includes the use of Asfotase alpha, which was approved by the Food and Drug Administration in 2015. Asfotase alpha is the first approved medication for the treatment of perinatal, infantile, and juvenile-onset hypophosphatasia. Also, Asfotase alpha is a recombinant human alkaline phosphatase available for long-term enzyme replacement to treat the bone manifestation of the disease. Another treatment used to improve the symptoms of hypophosphatasia includes drugs like NSAIDs and Vitamin B6.

Data Points	Key Statistics
Hypophosphatasia Treatment Market Value 2023	USD 15.36 Million
Hypophosphatasia Treatment Market Projected Value (2033)	USD 26.27 Million
Hypophosphatasia Treatment Market CAGR (2023 to 2033)	5.0%

Hypophospatasia Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for hypophosphatasia treatment is projected to increase at a CAGR of 5.0% during the forecast period between 2023 and 2033, reaching a total of USD 16.13 Million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 2.6%. According to Future Market Insights, a market research and competitive intelligence provider, the Hypophosphatasia Treatment market was valued at USD 15.36 Million in 2022.

As per the statistics published by the National Organization for Rare Disorders, Inc., there is an estimated annual incidence of hypophosphatasia is 1 in every 100,000 births in Canada. Factors such as the growing special designation from the regulatory authorities for the treatment of hypophosphatasia, coupled with the high demand for novel treatment are anticipated to boost the growth of the hypophosphatasia market over the analysis period.

Moreover, the increase in the demand for disease-specific novel treatment is another key factor that is projected to escalate the market growth in the coming years. In addition, huge financial support to the researchers for developing novel interventions is expected to augment the market growth in the near future. Also, the surge in special designation from the regulatory authorities to offer treatment to patients as quickly as possible is propelling the revenue share of the hypophosphatasia treatment market.

Which Drivers underpin Hypophospatasia Treatment Industry Expansion?

Family History of Hypophosphatasia to Fuel the Market Growth

The severe perinatal and infantile forms of hypophosphatasia are inherited as autosomal recessive conditions. The patient receives one defective gene from each parent. Some more mild (childhood or adult) hypophosphatasia cases are also inherited this way. Other mild adult as well as odontohypophospatasia cases seem to be inherited in an autosomal dominant pattern (the patient gets just one defective gene, not two, transmitted from one of his/her parents).

In this form, mild hypophosphatasia can occur from generation to generation. The perinatal form of hypophosphatasia can often be detected during pregnancy by ultrasound and by measuring ALP activity in chorionic villus samples from amniocentesis. Individuals with hypophosphatasia and parents of children with hypophosphatasia are encouraged to seek genetic counseling to explain the likelihood and severity of hypophosphatasia recurring in their families. This is a major factor that is projected to boost the growth of the market during the forecast period.

Rise in Prevalence of Hypophosphatasia to Accelerate the Market Growth

The rising incidence of genetic disorders characterized by the abnormal development of bones and teeth leads to Hypophosphatasia. These abnormalities occur due to defective mineralization such as calcium and phosphorus. These minerals are required for proper hardness as well as strength. Defective mineralization results in bones becoming soft and more prone to fracture.

Hypophosphatasia symptoms can vary greatly from one person to another, sometimes even among members of the same family. The disease is caused by mutations in the tissue nonspecific alkaline phosphatase (ALPL) gene, which is also known as the TNSALP gene. Such mutations lead to low activity of the tissue nonspecific alkaline phosphatase enzyme. Depending on the specific form, HPP can be inherited in an autosomal recessive or autosomal dominant manner. Thus, this is another major factor that is anticipated to fuel market growth in the forthcoming years.

Which Factors are limiting the Growth of Hypophospatasia Treatment Market?

Patent Expiration of Major Brands to Restrain the Market Growth

Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is one of the major factors that is expected to hamper the growth of the Hypophosphatasia Treatment Market during the forecast period.

Moreover, the patent expiration of major brands, coupled with the low healthcare budget in some developing regions will also impede market growth in the near future.

Fewer Treatment Options to Limit the Market Growth

Lack of skilled professionals or trained expertise in this area, in low-and-middle class economies, will hinder the way of market growth over the analysis period. In addition, factors including fewer treatment options available are likely to limit the growth of the hypophosphatasia treatment market in the coming years.

Region-wise Insights

Will North America Continue Dominance in the Global Hypophospatasia Treatment Market?

Increase in R&D Proficiencies in the Region to Fuel the Market Growth

The hypophosphatasia treatment market in North America is expected to accumulate the highest market share of 46% in 2023. Factors such as increasing research & development activities from major market players, and an increase in product offerings, are anticipated to fuel the regional market growth over the analysis period.

In addition, greater affordability, coupled with an increase in demand for early treatment are other major factors that will propel the Hypophosphatasia treatment market in North America in the coming years. The region is expected to hold the highest CAGR of 4.9% during the forecast period.

How Will the Growth of the Hypophosphatasia Treatment Market unfold in Asia Pacific?

Growing Demand for Hypophosphatasia Treatment in the Region to Fuel the Market Growth

The hypophosphatasia treatment market in Asia Pacific is expected to accumulate the highest market share of 44% in 2023. The Asia Pacific hypophosphatasia market is anticipated to register significant growth during the analysis period, attributed to factors such as an increase in the adoption of new products, and a rise in demand for hypophosphatasia treatment in emerging countries such as India and China.

Additionally, other factors including increasing awareness about the disease will also propel the market growth in Asia Pacific in the near future. The region is expected to hold the highest CAGR of 4.8% during the forecast period.

Category-wise Insights

By Type, which Hypophosphatasia Treatment Category will remain prominent?

Odontohypophospatasia Segment to beat Competition in Untiring Market

On the basis of type, the global Hypophosphatasia Treatment market is dominated by the Odontohypophospatasia Segment, which accounts for a share of 48%. The segment is expected to hold a CAGR of 4.9% over the analysis period.

The high segment’s growth is attributed to factors such as a high number of patients with odontoid hypophosphatasia, which is characterized by loss of premature teeth in childhood or loss of teeth in adulthood.

By Treatment Type, which Hypophosphatasia Treatment Category dominates?

Medication Segment to Drive the Hypophosphatasia Treatment Market

Based on treatment type, the medication segment is expected to witness a significant growth of 47% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.8% CAGR over the analysis period.

This growth is attributed to the launch of products for the treatment of hypophosphatasia from major manufacturers. For instance, in 2015, the USA Food and Drug Administration (FDA) approved Strensiq (asfotase alfa) as the first approved medical treatment for infantile, perinatal, and juvenile-onset HPP.

By Distribution Channel, which Hypophosphatasia Treatment Category dominates?

Hospital Pharmacies Segment to Drive the Hypophosphatasia Treatment Market

Based on the Distribution Channel, the hospital pharmacies segment is expected to witness a significant growth of 46% in 2022, and the trend is expected to continue during the forecast period, expanding at a 4.7% CAGR over the analysis period.

The segment’s significant growth is attributed to the fact that most of the major hypophosphatasia treatment products are prescription products, which are available in hospital pharmacies.

The Start-Up Ecosystem: How key Players are opening Frontiers for Future Growth?

Hypophosphatasia Treatment Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base.

• Founded in 2016, PuREC is a stem cell company with proprietary technology to provide the extremely purified stem cell, "REC". The company’s first therapeutic target is hypophosphatasia. In addition, many joint diseases, including spinal canal stenosis, are expected to be covered by “REC”.

Who are the Leading Players in the Hypophospatasia Treatment Market?

Prominent players in the hypophosphatasia treatment market are Kirin Holdings Company, Vericel Corporation, Mereo BioPharma Group plc., Novartis AG, AM-Pharma B.V., Alexion, Bayer AG, Enobia Pharma, and Pfizer, Inc., among others.

Recent Developments:

• In June 2021, Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, announced two publications of data on ARU-2801, a potentially curative gene therapy for people living with hypophosphatasia (HPP), in Molecular Therapy: Methods & Clinical Development and the Journal of Bone and Mineral Research (JBMR). To educate the HPP community about gene therapy, Aruvant had formed a partnership with Soft Bones, Inc., The USA Hypophosphatasia Foundation ("Soft Bones"), a leading advocacy group dedicated to the community of patients, caregivers, and families living with HPP.
• In September 2021, AstraZeneca established a rare disease business unit in China to introduce more innovative medicines in the country, targeting the complement system and beyond, for the treatment of rare diseases including PNH, aHUS, gMG, neuromyelitis optica spectrum disorder (NMOSD), hypophosphatasia, IgAN, LN, and amyloidosis.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 5.0% from 2023 to 2033
Market Value in 2023	USD 16.13 Million
Market Value in 2033	USD 26.27 Million
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Type, Treatment Type, End User, Region
Regions Covered	North America; Western Europe; Eastern Europe; Asia Pacific; Latin America; Middle East & Africa (MEA)
Key Countries Profiled	The USA, Canada, Brazil, Mexico, BENELUX, Germany, The UK, France, Spain, Italy, Nordics, Poland, Russia, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC, South Africa, Israel
Key Companies Profiled	PuREC; AstraZeneca; Aruvant Sciences; AM-Pharma; Railybio; Biometrix; Cook Medical; Grena; Redax; Lung Therapeutics Inc.
Customization & Pricing	Available upon Request

Key Segments Covered in the Hypophospatasia Treatment Industry Analysis

Hypophosphatasia Treatment Market by Type:

• Odontohypophospatasia
• Pseudohypophospatasia

Hypophosphatasia Treatment Market by Treatment Type:

• Medication
  • Asfotase Alfa
  • Non-steroidal Anti-inflammatory Drugs
  • Calcitonin
  • Strensiq
• Surgery

Hypophosphatasia Treatment Market by End User:

• Hospitals
• Pharmacies
• Others

Hypophosphatasia Treatment Market by Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific
• Middle East & Africa (MEA)

Frequently Asked Questions

What was the market value for hypophospatasia treatment in 2022?

As of 2022, the market for hypophospatasia treatment was valued at USD 15.36 Million, as per FMI

At what value did the Hypophospatasia Treatment Market close in 2023?

By 2023-end, sales of Hypophosphatasia Treatment closed at a value of USD 16.13 Million

What was the last 4 years’ value CAGR for Hypophospatasia Treatment?

From 2018 to 2022, Hypophospatasia Treatment demand expanded at a CAGR of 2.6%

What is the projected forecast CAGR for the Hypophospatasia Treatment Industry from 2023 to 2033?

From 2023 to 2033, Hypophosphatasia Treatment sales are expected to flourish at a CAGR of 5.0%

According to FMI, what is the anticipated market value for Hypophospatasia Treatment in 2033?

By 2033, the market value of Hypophospatasia Treatment is expected to reach USD 26.27 Million

By Type, which category ranks first with regard to Hypophospatasia Treatment?

By Type, the Odontohypophospatasia segment constitutes the bulk of market share of 48% in 2022

By Treatment Type, which category ranks first with regard to Hypophospatasia Treatment?

By treatment type, the medication segment dominates the market with a share of 47% in 2022.